Identification

Name
Bevantolol
Accession Number
DB01295
Type
Small Molecule
Groups
Approved
Description

Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension. Mechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors.

Structure
Thumb
Synonyms
  • (+-)-Bevantolol
  • 1-((2-(3,4-Dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol
  • 1-(3,4-Dimethoxyphenethylamino)-3-(m-tolyloxy)-2-propanol
  • 1-(3,4-Dimethoxyphenethylamino)-3-m-tolyloxy-propan-2-ol
  • 1-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-3-m-tolyloxy-propan-2-ol
  • Bevantololum
Categories
UNII
34ZXW6ZV21
CAS number
59170-23-9
Weight
Average: 345.4327
Monoisotopic: 345.194008357
Chemical Formula
C20H27NO4
InChI Key
HXLAFSUPPDYFEO-UHFFFAOYSA-N
InChI
InChI=1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3
IUPAC Name
1-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-3-(3-methylphenoxy)propan-2-ol
SMILES
COC1=C(OC)C=C(CCNCC(O)COC2=CC=CC(C)=C2)C=C1

Pharmacology

Indication

For the treatment of angina pectoris and hypertension.

Structured Indications
Not Available
Pharmacodynamics

Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension.

Mechanism of action

Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors. By binding and antagonizing beta-1 receptors Bevantolol inhibits the normal normal epinephrine-mediated sympathetic actions such as increased heart rate. This has the effect of decreasing preload and blood pressure.

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
UBeta-2 adrenergic receptor
antagonist
Human
UAlpha-1A adrenergic receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Bevantolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Bevantolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Experimental, Illicit
AceclofenacAceclofenac may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Bevantolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Bevantolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Bevantolol.Approved
AcetohexamideBevantolol may increase the hypoglycemic activities of Acetohexamide.Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Acetylcholine.Approved
AcetyldigitoxinBevantolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinBevantolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Bevantolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Experimental, Investigational
AlaproclateThe serum concentration of Bevantolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Bevantolol.Approved, Withdrawn
AlfentanilAlfentanil may increase the bradycardic activities of Bevantolol.Approved, Illicit
AlfuzosinBevantolol may increase the orthostatic hypotensive activities of Alfuzosin.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Bevantolol.Approved, Vet Approved
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Bevantolol.Experimental
AmbenoniumAmbenonium may increase the bradycardic activities of Bevantolol.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Bevantolol.Approved, Investigational
AmobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Bevantolol can be decreased when combined with Amodiaquine.Approved, Investigational
AndrographolideAndrographolide may decrease the antihypertensive activities of Bevantolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Bevantolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Bevantolol.Approved
ApocyninApocynin may decrease the antihypertensive activities of Bevantolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
ApremilastApremilast may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Arecoline.Experimental
AzapropazoneAzapropazone may decrease the antihypertensive activities of Bevantolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Bevantolol.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
BarbexacloneThe serum concentration of Bevantolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Barbital.Illicit
BendazacBendazac may decrease the antihypertensive activities of Bevantolol.Experimental
BenorilateBenorilate may decrease the antihypertensive activities of Bevantolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Bevantolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Illicit
BethanecholThe risk or severity of adverse effects can be increased when Bevantolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Bevantolol.Experimental
BL-1020BL-1020 may increase the hypotensive activities of Bevantolol.Investigational
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Bevantolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Bevantolol.Investigational
BucindololBevantolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Bevantolol.Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Bevantolol.Experimental
BunazosinBevantolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Bevantolol.Approved, Investigational
CabergolineBevantolol may increase the vasoconstricting activities of Cabergoline.Approved
CarbacholThe risk or severity of adverse effects can be increased when Bevantolol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Bevantolol.Experimental, Investigational
CarbutamideBevantolol may increase the hypoglycemic activities of Carbutamide.Experimental
CarprofenCarprofen may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved, Withdrawn
CarvedilolBevantolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Bevantolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Bevantolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Bevantolol.Experimental
ChlorpromazineChlorpromazine may increase the hypotensive activities of Bevantolol.Approved, Vet Approved
ChlorpropamideBevantolol may increase the hypoglycemic activities of Chlorpropamide.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Bevantolol.Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Bevantolol.Approved
CoumaphosCoumaphos may increase the bradycardic activities of Bevantolol.Vet Approved
CurcuminCurcumin may decrease the antihypertensive activities of Bevantolol.Investigational
CymarinBevantolol may increase the bradycardic activities of Cymarin.Experimental
D-LimoneneD-Limonene may decrease the antihypertensive activities of Bevantolol.Investigational
DapoxetineThe serum concentration of Bevantolol can be increased when it is combined with Dapoxetine.Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Bevantolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Bevantolol.Approved
DeslanosideBevantolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Bevantolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Vet Approved
DichlorvosDichlorvos may increase the bradycardic activities of Bevantolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Bevantolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Bevantolol.Approved
DigitoxinBevantolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinBevantolol may increase the bradycardic activities of Digoxin.Approved
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
DiltiazemDiltiazem may increase the hypotensive activities of Bevantolol.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Bevantolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Bevantolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Bevantolol.Experimental
DonepezilDonepezil may increase the bradycardic activities of Bevantolol.Approved
DoxazosinBevantolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DronedaroneDronedarone may increase the bradycardic activities of Bevantolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Bevantolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
DuloxetineThe serum concentration of Bevantolol can be increased when it is combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Bevantolol.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Bevantolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Bevantolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Bevantolol.Approved
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Bevantolol.Approved
Ergoloid mesylateBevantolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineBevantolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Bevantolol.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Bevantolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
EtoperidoneThe serum concentration of Bevantolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
exisulindexisulind may decrease the antihypertensive activities of Bevantolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Bevantolol.Experimental
FenbufenFenbufen may decrease the antihypertensive activities of Bevantolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Bevantolol.Approved
FentanylFentanyl may increase the bradycardic activities of Bevantolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Bevantolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Bevantolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Bevantolol.Experimental
Ferulic acidFerulic acid may decrease the antihypertensive activities of Bevantolol.Experimental
FingolimodBevantolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Bevantolol.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Bevantolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Bevantolol.Experimental
FluoxetineThe serum concentration of Bevantolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Bevantolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Bevantolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Bevantolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Bevantolol.Approved, Investigational, Nutraceutical
GitoformateBevantolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideBevantolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideBevantolol may increase the hypoglycemic activities of Gliclazide.Approved
GlipizideBevantolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneBevantolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideBevantolol may increase the hypoglycemic activities of Glisoxepide.Approved, Investigational
GlyburideBevantolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Bevantolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Bevantolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
HexobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Bevantolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Bevantolol.Investigational
HydroxychloroquineThe metabolism of Bevantolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Bevantolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Bevantolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Bevantolol.Approved
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Bevantolol.Experimental
IndalpineThe serum concentration of Bevantolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndobufenIndobufen may decrease the antihypertensive activities of Bevantolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Bevantolol.Withdrawn
IndoraminBevantolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkBevantolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Bevantolol.Experimental
IsoflurophateIsoflurophate may increase the bradycardic activities of Bevantolol.Approved, Investigational, Withdrawn
IsoxicamIsoxicam may decrease the antihypertensive activities of Bevantolol.Withdrawn
KebuzoneKebuzone may decrease the antihypertensive activities of Bevantolol.Experimental
KetoprofenKetoprofen may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Bevantolol.Approved
LabetalolBevantolol may increase the orthostatic hypotensive activities of Labetalol.Approved
Lanatoside CBevantolol may increase the bradycardic activities of Lanatoside C.Experimental
LeflunomideLeflunomide may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
LevomilnacipranThe serum concentration of Bevantolol can be increased when it is combined with Levomilnacipran.Approved
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Bevantolol.Approved, Vet Approved
LisofyllineLisofylline may decrease the antihypertensive activities of Bevantolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Bevantolol.Experimental
LornoxicamLornoxicam may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Bevantolol.Approved
MalathionMalathion may increase the bradycardic activities of Bevantolol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Bevantolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Bevantolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Bevantolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Bevantolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Bevantolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Bevantolol.Approved, Investigational
MetahexamideBevantolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Bevantolol.Investigational, Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Methacholine.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Bevantolol.Investigational
MethohexitalThe serum concentration of Bevantolol can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Bevantolol.Approved
Methyl salicylateMethyl salicylate may increase the bradycardic activities of Bevantolol.Approved, Vet Approved
Methylene blueMethylene blue may increase the hypotensive activities of Bevantolol.Approved, Investigational
MethylergometrineBevantolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinBevantolol may increase the bradycardic activities of Metildigoxin.Experimental
MetoclopramideMetoclopramide may increase the bradycardic activities of Bevantolol.Approved, Investigational
MidodrineBevantolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Bevantolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Bevantolol.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Bevantolol.Investigational
MofebutazoneMofebutazone may decrease the antihypertensive activities of Bevantolol.Experimental
MoricizineMoricizine may increase the hypotensive activities of Bevantolol.Approved, Investigational, Withdrawn
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Bevantolol.Approved
NabumetoneNabumetone may decrease the antihypertensive activities of Bevantolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Bevantolol.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
NefazodoneThe serum concentration of Bevantolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Bevantolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Bevantolol.Approved
NicotineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Nicotine.Approved
NifedipineNifedipine may increase the hypotensive activities of Bevantolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Bevantolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Bevantolol.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Bevantolol.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Bevantolol.Investigational
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
OleandrinBevantolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Bevantolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Bevantolol.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Bevantolol.Vet Approved
OuabainBevantolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Bevantolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Bevantolol.Approved, Withdrawn
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
ParaoxonParaoxon may increase the bradycardic activities of Bevantolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Bevantolol.Approved
ParoxetineThe serum concentration of Bevantolol can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Bevantolol.Investigational
PentobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerazinePerazine may increase the hypotensive activities of Bevantolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational, Vet Approved, Withdrawn
PerphenazinePerphenazine may increase the hypotensive activities of Bevantolol.Approved
PeruvosideBevantolol may increase the bradycardic activities of Peruvoside.Experimental
PhenobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Phenobarbital.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Bevantolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
PirfenidonePirfenidone may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Bevantolol.Experimental
PranoprofenPranoprofen may decrease the antihypertensive activities of Bevantolol.Experimental, Investigational
PrazosinBevantolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Bevantolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Bevantolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Bevantolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Bevantolol.Experimental
PromazinePromazine may increase the hypotensive activities of Bevantolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Bevantolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
PropafenoneThe serum concentration of Bevantolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Bevantolol.Vet Approved
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Bevantolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Bevantolol.Experimental
ProscillaridinBevantolol may increase the bradycardic activities of Proscillaridin.Experimental
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Bevantolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Bevantolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Bevantolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Bevantolol.Approved
ReserpineReserpine may increase the hypotensive activities of Bevantolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Bevantolol.Approved, Experimental, Investigational
RifampicinThe serum concentration of Bevantolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Bevantolol can be decreased when it is combined with Rifapentine.Approved
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
RivastigmineRivastigmine may increase the bradycardic activities of Bevantolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Bevantolol.Investigational, Withdrawn
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved, Investigational
SalicylamideSalicylamide may decrease the antihypertensive activities of Bevantolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Bevantolol.Approved, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Bevantolol.Approved
SecobarbitalThe serum concentration of Bevantolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SemapimodSemapimod may decrease the antihypertensive activities of Bevantolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Bevantolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Bevantolol.Investigational
SertralineThe serum concentration of Bevantolol can be increased when it is combined with Sertraline.Approved
SilodosinBevantolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SRT501SRT501 may decrease the antihypertensive activities of Bevantolol.Investigational
SufentanilSufentanil may increase the bradycardic activities of Bevantolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Bevantolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Bevantolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Bevantolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Bevantolol.Experimental
TacrineTacrine may increase the bradycardic activities of Bevantolol.Investigational, Withdrawn
TamsulosinBevantolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Bevantolol.Investigational
TenidapTenidap may decrease the antihypertensive activities of Bevantolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Bevantolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Bevantolol.Vet Approved
TerazosinBevantolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Bevantolol.Approved
ThiamylalThe serum concentration of Bevantolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Bevantolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Bevantolol.Withdrawn
ThiopentalThe serum concentration of Bevantolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThioridazine may increase the hypotensive activities of Bevantolol.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Bevantolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Bevantolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
TolazamideBevantolol may increase the hypoglycemic activities of Tolazamide.Approved
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Bevantolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Bevantolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
TribenosideTribenoside may decrease the antihypertensive activities of Bevantolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Bevantolol.Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Bevantolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Bevantolol.Approved, Vet Approved
TrimazosinBevantolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TriptolideTriptolide may decrease the antihypertensive activities of Bevantolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Bevantolol.Approved
UrapidilBevantolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Bevantolol.Investigational, Withdrawn
VareniclineThe risk or severity of adverse effects can be increased when Bevantolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Bevantolol can be increased when it is combined with Venlafaxine.Approved
VerapamilVerapamil may increase the hypotensive activities of Bevantolol.Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Bevantolol.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Bevantolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Bevantolol can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracZomepirac may decrease the antihypertensive activities of Bevantolol.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Yutaka Nomura, "Process for preparation of bevantolol hydrochloride." U.S. Patent US5382689, issued December, 1974.

US5382689
General References
  1. Vaughan Williams EM: Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. J Clin Pharmacol. 1987 Jul;27(7):450-60. [PubMed:2888789]
External Links
Human Metabolome Database
HMDB15409
PubChem Compound
2372
PubChem Substance
46506014
ChemSpider
2282
ChEBI
238698
ChEMBL
CHEMBL314010
Therapeutic Targets Database
DAP000897
PharmGKB
PA164743236
ATC Codes
C07AB06 — BevantololC07BB06 — Bevantolol and thiazides

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)137-138 °CPhysProp
logP3.00HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0137 mg/mLALOGPS
logP2.83ALOGPS
logP3.03ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.31ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area59.95 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity98.54 m3·mol-1ChemAxon
Polarizability39.75 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8271
Blood Brain Barrier-0.9297
Caco-2 permeable-0.6012
P-glycoprotein substrateSubstrate0.8119
P-glycoprotein inhibitor IInhibitor0.625
P-glycoprotein inhibitor IIInhibitor0.8061
Renal organic cation transporterNon-inhibitor0.6935
CYP450 2C9 substrateNon-substrate0.7741
CYP450 2D6 substrateSubstrate0.5792
CYP450 3A4 substrateSubstrate0.5727
CYP450 1A2 substrateNon-inhibitor0.6261
CYP450 2C9 inhibitorNon-inhibitor0.9068
CYP450 2D6 inhibitorNon-inhibitor0.7311
CYP450 2C19 inhibitorNon-inhibitor0.9218
CYP450 3A4 inhibitorNon-inhibitor0.6133
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9339
Ames testNon AMES toxic0.9124
CarcinogenicityNon-carcinogens0.926
BiodegradationNot ready biodegradable0.8696
Rat acute toxicity2.0966 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6187
hERG inhibition (predictor II)Inhibitor0.8681
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dimethoxybenzenes. These are organic aromatic compounds containing a monocyclic benzene moiety carrying exactly two methoxy groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Methoxybenzenes
Direct Parent
Dimethoxybenzenes
Alternative Parents
Phenethylamines / Phenoxy compounds / Anisoles / Toluenes / Aralkylamines / Alkyl aryl ethers / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds
show 1 more
Substituents
Dimethoxybenzene / O-dimethoxybenzene / Phenethylamine / Anisole / Phenol ether / Phenoxy compound / Alkyl aryl ether / Aralkylamine / Toluene / 1,2-aminoalcohol
show 13 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
propanolamine (CHEBI:238698)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Hino T, Sakai K, Ichihara K, Abiko Y: Attenuation of ischaemia-induced regional myocardial acidosis by bevantolol, a beta 1-adrenoceptor antagonist, in dogs. Pharmacol Toxicol. 1989 Apr;64(4):324-8. [PubMed:2568629]
  2. Dukes ID, Vaughan Williams EM: Cardiovascular effects of bevantolol, a selective beta 1-adrenoceptor antagonist with a novel pharmacological profile. Br J Pharmacol. 1985 Feb;84(2):365-80. [PubMed:2858236]
  3. Lofdahl CG, Svedmyr K, Svedmyr N: Selectivity of bevantolol hydrochloride, a beta 1-adrenoceptor antagonist, in asthmatic patients. Pharmacotherapy. 1984 Jul-Aug;4(4):205-10. [PubMed:6148733]
  4. Vaughan Williams EM: Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. J Clin Pharmacol. 1987 Jul;27(7):450-60. [PubMed:2888789]
  5. Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16. [PubMed:17628611]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16. [PubMed:17628611]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Shiraishi K, Moriya M, Miyake N, Takayanagi I: Alpha 1-adrenoceptor blocking activities of bevantolol hydrochloride(NC-1400) and labetalol in rat isolated thoracic aorta--do they distinguish between subtypes? Gen Pharmacol. 1992 Sep;23(5):843-5. [PubMed:1358746]

Drug created on June 30, 2007 08:18 / Updated on November 09, 2017 02:58